- Home
- ERNAW vs BRKRP Comparison
ERNAW vs BRKRP Comparison
Compare ERNAW & BRKRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERNAW | BRKRP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ERNAW | BRKRP |
|---|---|---|
| Price | $0.06 | $431.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.5K | 1.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $582,000.00 | ★ $1,895,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $256.35 |
| 52 Week High | $0.23 | $474.99 |
Technical Indicators
Market Signals| Indicator | ERNAW | BRKRP |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 51.97 |
| Support Level | $0.03 | $425.25 |
| Resistance Level | $0.08 | $445.12 |
| Average True Range (ATR) | 0.02 | 8.29 |
| MACD | 0.00 | 0.63 |
| Stochastic Oscillator | 76.37 | 64.09 |
Price Performance
Historical ComparisonAbout ERNAW Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
About BRKRP Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.